Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
More RSI News
Working with international thought leaders in risk science, Risk Sciences International investigators contributed to the development of the evidenced-based risk assessment framework shown in the…Read News Item
Problem Formulation in Food Safety Assessments conducted by the European Food Safety Authority RSI investigators recently provided advise to the European Food Safety Authority (EFSA)…Read News Item
In its 2007 report on Toxicity Testing in the 21st Century: A Vision and a Strategy, the US National Research Council (NRC) highlighted need for more rapid…Read News Item
RSI investigators propose fundamental principles of risk decision-making, and explore their application in a range of real-world risk decision-making contexts. These ten principles will provide valuable guidance on addressing current and future risk issues facing civil societies worldwide.Read News Item